- World Pharma News Home » Product » First interleukin-6 inhibitor (IL-6) to offer new therapeutic option for rheumatoid arthritis
(a free service delivered by FeedBurner)
Roche announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) vote recommended approval of Actemra (tocilizumab), a novel interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA).
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments